Please login to the form below

The 'winner takes all' pricing game

Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.

Pharmaceutical tendering and contracting is now approximately a quarter of total global turnover, though this is just an estimate as the level of tendering is market- and product-dependent. The impact of tendering on pharmaceutical business, however, is mainly through price erosion.

Open tendering, which means all suppliers are invited to bid, results in the lowest prices, especially when many suppliers are interested in the contract. Other drivers of price erosion include high prices, high volumes, and tendering by 'winner takes all' where there are alternatives available.

We developed a pricing game where the participants are split into competitive teams that are bidding for the business of six hospitals. Each hospital is tendering for full volume in a 'winner takes all' market. The hospitals have different volume needs, incumbent player(s) at the start of the game and price sensitivity, and participants know or can imply these characteristics from the hospital descriptions. The game has pre-set award conditions, threshold to switch (if any), growth rates by customer, and 'attractiveness' to the customers.

As the game continues, teams take on new roles, for example with a new entry of a branded or generic competitor, where more and more competitors are pitching to the same set of customers. There are three to six rounds of bidding, and after each round the teams get the results of their bids and prepare for the next round.

Repeating the pricing game with different players can lead to different results.

A key point of price competition is while authorities or customers set the conditions to allow price competition, it is the competitive behaviour of the teams that defines the intensity of price erosion. The speed of price erosion is function of the number of competitors, aggressivity of the players, and the lowest cost of goods in the game.

For the customer, tendering can be an efficient tool for lowering prices, but there are also challenges:

  • Difficulties in estimating quantity of product required
  • Requirement for expertise and resources; may need dedicated teams
  • May be complicated by legal issues
  • May lead to supply problems

From the company side, tendering may offer a chance to break through the monopoly of an incumbent competitor. It can also increase transparency and lower risk for fraud. However, efficient tendering can significantly cut profits, so much that it may reduce the number of suppliers. This in turn could raise prices and increase the risk of shortages.

The system can be made more sustainable by reducing the administrative burden through pre-qualifications and electronic bidding systems. Contracts may be split between two or more suppliers, to minimize the risk of shortages and to maintain long-term competition.

On the industry side, focus is mainly on communicating the risks of tendering:

  • Quality risks when lowest price is the dominant criterion
  • Medical risks when substituting one product for another
  • Shortages when 'winner takes all' tenders are used
  • Lack of optimization of medical therapy by treating all patients alike.

In the market, companies will try to get out of the 'winners take all' and 'lowest price' paradigms by differentiating products through formulation or delivery systems.

What seems to be missing on the industry side is the understanding that price erosion in tendering markets is strongly influenced by their own behaviour. In the tendering environment, aggressive price cutting seems to be the rule rather than the exception. One of the core reasons is that almost all pharmaceutical companies use market share and sales as the most important key performance indicators of commercial and management functions.

Conclusions

Pharmaceutical tendering will stay as a key procurement approach for pharmaceutical products, especially for hospital products but also in outpatient settings for generics/biosimilars or other segments of products with low differentiation. All stakeholders are recognising the opportunities and risks of efficient tendering.

We should expect a reduction of the 'winner takes all' lowest price tenders, however customers will keep searching for the best balance between low price and sustainable high-quality supply.

To find out how Valid Insight can support you in  pricing & negotiation, contact us at discover@validinsight.com.

20th November 2019

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the evaluation of health and healthcare interventions.
Valid Insight
Pricing and Market Access Simulator
Reliable tool for value assessment of pipeline products
Valid Insight
Virtual workshops to elevate value, pricing and market access strategies
This blog post explores how well-facilitated virtual workshops can be just as valuable as face-to-face meetings.
Valid Insight
Putting people and the planet first in 2020
Valid Insight go paperless to promote environmental sustainability within the pharmaceutical industry
Valid Insight
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to get a return on investment.  What are the implications for pharma and biotech market access?
Valid Insight
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step.
Valid Insight